REVIEWS:
The introduction
After all participants had found a seat richly filled with presents, Mrs. Larissa Blatter of the SSAC association gave us a warm welcome.
After a brief presentation of the association and its goals by Grégory Schaeffer, we had the honor of hearing Ms. S.Stauffer from the Ins retirement center speak about the potential of medical cannabis in elderly care. Based on models such as Tikun Olam in Israel, the use of cannabis in Europe / Switzerland is also easy to imagine. The hurdles for this are smoothed out every year. A promising approach.
However, as activism declines, the market could likely be mostly reserved for synthetic, laboratory-developed cannabinoids.
The interaction of the endo- and phytocannabinoids
presented by Prof. em. Dr. pharm. Rudolf Brenneisen
Phytocannabinoids = biogenic cannabinoids from the Cannabis sativa L. plant,> 110
Endocannabinoids = the body's own cannabinoids that interact with the ECS
ECS endocannabinoid system
Hyper- or hypofunction of the ECS can trigger pathological phenomena and disrupt homeostasis.
The pharmacological potential of cannabinoids results primarily from the direct and indirect modulation of the ECS. In other words, the medical benefit of cannabis lies in the targeted manipulation of the body's own system (ECS).
Here is an overview of some groundbreaking scientific discoveries;
-
1988 the first cannabinoid receptor, the CB1 receptor.
This occurs in all mammals, but not in insects.
-
1992 Endocannabinoids: arachidonylethanolamide, anandamide = AEA
-
1993 second cannabinoid receptor, CB2 receptor
-
1994 Synthetic CB1-R antagonist -> SR 141716A, Acomplia® (Sanofi)
-
1997 CB1- & CB2-R ligand -> arachidonylglycerol, 2-AG
-
2001 CB1- & CB2-R ligand -> 2-arachidonyl glyceryl ether, 2-AGE, noladine ether
-
2000- 2002 CB1- & TRPV1 (Vanilloid) -R Ligand -> N-arachidonoyldopamine, NADA
-
2002 CB1- & CB2-R ligand -> O-arachidonoylethanolamine, virodhamin, O-AEA
-
2007 CB3-R -> G-protein coupled receptor 55, GPR55
The ECS is a key player involved in:
Effects of THC, processing of negative memories, mental illnesses, fear, sleep, pain, movement control, appetite
With the so-called “jogger high” it is known that more endorphins and endocannabinoids are released.
CB1 receptors are mainly located in the brain. The activation thus also affects our reward system.
SOURCE: Prof. em. Dr. pharm. Rudolf Brenneisen
Secretary General Schw. Akad. Pharm. Wiss. www.saphw.ch , head of the Schw. working group cannabinoids in medicine, research group leader Dep. Clin. Research Univ. Bern (until 2014)
Therapeutic targets:
-A 66 year old woman has an FAAH defect. FAAH is responsible for the breakdown of the anandamide. This means that her anandamide level is increased and she therefore cannot feel any pain.
-Liver diseases
Immunosuppressive? Therapeutic approach to HCV infections?
-Migraine
The metabolism and removal of anandamide is increased in women. Does the low concentration lower the pain threshold?
-Pain in animal studies
CB1-R agonists are potent analgesics in the animal model of neuropathic pain.
CB1-R agonists act on the part of the brain that is important for the relief of neuropathic pain.
- pain
Dafalgan, for example, also works through the ECS.
-Psychoses
8 times higher AEA level in antipsychotic schizophrenia patients.
CBD has a similar effect to the drug amisulpride.
SOURCE: Prof. em. Dr. pharm. Rudolf Brenneisen
Secretary General Schw. Akad. Pharm. Wiss. www.saphw.ch , head of the Schw. working group cannabinoids in medicine, research group leader Dep. Clin. Research Univ. Bern (until 2014)
The aperitif afterwards:
After a few rejections, the organizers were nevertheless surprised by the large number of participants. The great aperitif buffet with a refreshing white wine from the region could now be enjoyed at nicely decorated bar tables. The information stand presented new specialist books and information on everyday use such as the safe consumption of cannabis.
The exciting lecture by Prof. em. Dr. pharm. Rudolf Brenneisen invited to an inspired exchange. Company owners, pharmaceutical employees, participants from the medical field, as well as cannatrade legend M. Kuhn, quickly found the conversation about research and the future of the cannabis plant in medicine.
Conclusion: Nobody could learn anything and everybody had the opportunity to ask the questions that are / will be of interest in reality and in the near future.
Relationships were strengthened and new ones made.
A really great event with very motivated speakers and participants;
THANK YOU SSAC and see you next time!
